Gastric Inhibitory Polypeptide Receptor
GIPR is the receptor for GIP, the second incretin hormone. It is the target of the GIP arm of tirzepatide and retatrutide. The Glu354Gln variant (rs1800437) lowers GIPR function, and carriers are more likely to get moderate-to-severe nausea and vomiting on GIP-active drugs. The variant doesn't matter for GLP-1-only drugs like semaglutide.
Gene2Rx reports your GIPR genotype across 2 named alleles, built from 1 variant curated by PharmVar.
GIPR alleles are named by the underlying DNA variant rather than a star number — for example c.61C>T describes a single base change at position 61 of the coding sequence.
You inherit one allele from each parent, and the pair determines whether your GIPR activity is normal, decreased, or absent.
PharmVar is the international registry that curates these names. Gene2Rx tests every variant needed to call each cataloged GIPR allele.
Gene2Rx covers 2 medications with published pharmacogenetic guidance for GIPR, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.
These branded medications include at least one active ingredient whose metabolism or action involves GIPR. Each links to its full pharmacogenetic breakdown.
This page lists drugs affected by GIPR. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.
Get your report Look up a medicationInformational only, not medical advice. The presence of a GIPR pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.